The HMGN3 Knockout Jurkat Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human Jurkat T lymphocyte line. This product contains a heterogeneous pool of cells with targeted disruption of the HMGN3 gene, leading to loss of functional HMGN3 expression. CRISPR/Cas9-mediated gene editing introduces diverse mutations at the HMGN3 locus, creating a polyclonal loss-of-function model that avoids clonal biases.
The Jurkat cell line originates from an acute T cell leukemia patient and serves as an immortalized human T lymphocyte model extensively used in T cell signaling, leukemia, and chromatin biology research. Its well-characterized response to activation stimuli and human genetic background make it an ideal host for investigating gene regulatory mechanisms in a hematopoietic context.
HMGN3 is a nucleosome-binding protein that reduces chromatin compaction and enhances transcription factor access. It directly interacts with nucleosomes, linker histone H1, DVL2, and ??-catenin, positioning it at the interface of chromatin remodeling and Wnt/??-catenin signaling. Upstream, Wnt ligands and TCF/LEF transcription factors regulate HMGN3, while downstream it modulates expression of Wnt targets like MYC and CCND1. Thus, HMGN3 coordinates chromatin architecture with transcriptional output, influencing cell proliferation and differentiation.
In Jurkat T cells, HMGN3 loss disrupts normal chromatin organization, altering Wnt/??-catenin-dependent gene expression and potentially compromising T cell activation and proliferation. This model is particularly relevant for studying leukemogenesis and cancers where dysregulated chromatin and Wnt signaling drive pathogenesis. The polyclonal knockout cells enable dissection of HMGN3’s role in T cell leukemia without clonal artifacts.
Researchers can use these cells to examine HMGN3’s function in T cell receptor signaling, chromatin state dynamics, and genome-wide transcription. Typical experimental approaches include western blotting, RT?qPCR, RNA?seq, ATAC?seq, ChIP?qPCR, flow cytometry, cell proliferation and apoptosis assays, Wnt reporter assays, and co-immunoprecipitation. This polyclonal knockout model supports detailed mechanistic studies and drug discovery efforts targeting chromatin and Wnt pathways in leukemia. For further inquiries, please contact Ascent Research.
